Potential values.3 Sep 2025 20:29
Estimates for the potential sales of p140 peptide are highly speculative, as the drug, also known as Lupuzor or Forigerimod, is still in clinical trials. Market forecasts depend on several factors, including regulatory approval, pricing, success against competitors, and its eventual indication. ImmuPharma, the developer of p140, projects that if the drug is approved for Systemic Lupus Erythematosus (SLE), it could enter a market with the potential for "multi-billion dollar sales".